



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lacmmle et al.)	Group Art Unit: 1652	
Applica	ation No.: 09/833328)	Examiner:	Malgorzata A. Walicka
Filed:	April 12, 2001)		
)	COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV)		

Assistant Commissioner for Patents Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Claims 1-35 are pending in the present application. In the Office Action mailed October 24, 2002, the Examiner requested that Applicants elect to prosecute one of the following groups of claims pursuant 35 U.S.C. §121:

Group I - Claims 1-26, 29 and 30-31, drawn to polypeptide having vWF protease activity and its compositions, classifed in class 435, subclass 219, for example.

Group II - Claims 32-33, drawn to DNA, host cell and recombinant method of production of the polypeptide of Group I, classified in class 536, subclass 23.2, for example.

Group III - Claim 27, drawn to the use of the polypeptide for the development of antibodies, classified in class 424, subclass 130.1, for example.

Group IV - Claim 28, drawn to a method of purifying von Willebrand factor, classified in class, 530, subclass 412, for example.

Group V - Claim 34 and 35 drawn to a use of polypeptide of Group I for the production of the preparation for the prophylaxis or therapy; the method is indefinite, classification unknown.

Feb 24 2003

Applicants hereby elect to prosecute the claims of Group I, with traverse. If there are any questions regarding this Response to Restriction Requirement, please telephone the undersigned at (805) 372-3553.

Respectfully submitted,

Baxter Healthcare Corporation Post Office Box 15210 Ivine, Ca 92623-5210

Registration No 36,799 Facsimile: (805) 372-3562

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this document (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV201037625US, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on February 24 2003